These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21985636)

  • 1. Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation.
    Bae HM; Lee JH; Yoon JH; Kim YJ; Heo DS; Lee HS
    BMC Cancer; 2011 Oct; 11():435. PubMed ID: 21985636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels.
    Kang SH; Kim DY; Jeon SM; Ahn SH; Park JY; Kim SU; Kim JK; Lee KS; Chon CY; Han KH
    Eur J Gastroenterol Hepatol; 2012 Jul; 24(7):849-56. PubMed ID: 22495400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
    Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
    World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification.
    Kamiyama T; Orimo T; Wakayama K; Shimada S; Nagatsu A; Yokoo H; Kamachi H; Yamashita K; Shimamura T; Taketomi A
    World J Surg Oncol; 2017 Aug; 15(1):156. PubMed ID: 28830473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
    Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
    Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma.
    Ricco G; Cosma C; Bedogni G; Biasiolo A; Guarino M; Pontisso P; Morisco F; Oliveri F; Cavallone D; Bonino F; Plebani M; Brunetto MR
    Cancer Biomark; 2020; 29(2):189-196. PubMed ID: 32623383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
    Feng H; Li B; Li Z; Wei Q; Ren L
    BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein.
    Suehiro T; Sugimachi K; Matsumata T; Itasaka H; Taketomi A; Maeda T
    Cancer; 1994 May; 73(10):2464-71. PubMed ID: 7513601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of the γ-glutamyltransferase and alanine transaminase ratio, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist II in hepatitis B virus-related hepatocellular carcinoma.
    Wang G; Lu X; Du Q; Zhang G; Wang D; Wang Q; Guo X
    Sci Rep; 2020 Aug; 10(1):13519. PubMed ID: 32782270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients.
    Xu F; Zhang L; He W; Song D; Ji X; Shao J
    Dis Markers; 2021; 2021():8868370. PubMed ID: 33628341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival.
    Nanashima A; Taura N; Abo T; Ichikawa T; Sakamoto I; Nagayasu T; Nakao K
    Dig Dis Sci; 2011 Oct; 56(10):3086-100. PubMed ID: 21706206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
    Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
    Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma.
    Kato H; Yoshida H; Taniguch H; Nomura R; Sato K; Suzuki I; Nakata R
    World J Gastroenterol; 2015 Dec; 21(46):13101-12. PubMed ID: 26673627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma.
    Wang Q; Chen Q; Zhang X; Lu XL; Du Q; Zhu T; Zhang GY; Wang DS; Fan QM
    World J Gastroenterol; 2019 Sep; 25(36):5515-5529. PubMed ID: 31576097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection.
    Kim DY; Paik YH; Ahn SH; Youn YJ; Choi JW; Kim JK; Lee KS; Chon CY; Han KH
    Oncology; 2007; 72 Suppl 1():52-7. PubMed ID: 18087182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
    Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V
    J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.
    Abd El Gawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
    J Egypt Natl Canc Inst; 2014 Jun; 26(2):79-85. PubMed ID: 24841158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic analysis of stage II-III hepatocellular carcinoma showing early massive recurrence after liver resection.
    Yamanaka J; Yamanaka N; Nakasho K; Tanaka T; Ando T; Yasui C; Kuroda N; Takata M; Maeda S; Matsushita K; Uematsu K; Okamoto E
    J Gastroenterol Hepatol; 2000 Oct; 15(10):1192-8. PubMed ID: 11106101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) predicts complete responses of transarterial chemoembolization for hepatocellular carcinoma.
    Wang SY; Su TH; Chen BB; Liu CJ; Liu CH; Yang HC; Tseng TC; Chen PJ; Kao JH
    J Formos Med Assoc; 2022 Aug; 121(8):1579-1587. PubMed ID: 35078686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.